Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

Integrated multi-omic profiling identifies molecular subtypes and predicts outcomes in newly diagnosed peripheral T-cell lymphomas

Blood (2025) 146 (Supplement 1): 1758.

https://doi.org/10.1182/blood-2025-1758

Published: 2025

Journal Articles

Increased incidence of secondary malignancies after autologous stem cell transplantation in follicular lymphoma patients: Long-term results of the FIL-FLAZ12 Phase III randomized trial

Blood (2025) 146 (Supplement 1): 5364.

https://doi.org/10.1182/blood-2025-5364

Published: 2025

Journal Articles

Longitudinal Monitoring of Circulating Tumor DNA to Predict Survival in Newly Diagnosed Peripheral T-Cell Lymphoma Patients

Blood (2024) 144 (Supplement 1): 1580.

https://doi.org/10.1182/blood-2024-201391

Published: 2024

Journal Articles

Impact of Concurrent and Previous Multidrug Resistant Bacteria Colonization in Adult Allogenic Hematopoietic Stem Cell Transplant Patients with Acute Leukemia: A Single Center Retrospective Study

Alessandra Vatteroni, Alberto Schena, Fulvia Mazzaferri, Francesca Lutteri, Simone Cesaro, Mauro Krampera, Fabio Benedetti, Cristina Tecchio

Blood (2023) 142 (Supplement 1): 6966.

https://doi.org/10.1182/blood-2023-187359

Published: 2023

Journal Articles

Impact of Fourth Methotrexate Dose in ATG-Cyclosporine GvHD Prophylaxis in HLA-Matched Unrelated HSCT: A GITMO Study

Blood (2022) 140 (Supplement 1): 10514–10516.

https://doi.org/10.1182/blood-2022-162853

Published: 2022

Journal Articles

The Addition of Romidepsin to CHOEP and High-Dose Chemotherapy Plus Stem Cell Transplantation Did Not Ameliorate the Outcome of Untreated Angioimmunoblastic T-Cell or Follicular T-Helper Lymphoma: Subgroup Analysis of Phase II FIL-PTCL13 Study

Blood (2022) 140 (Supplement 1): 6538–6539.

https://doi.org/10.1182/blood-2022-163824

Published: 2022

Journal Articles

Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma

Blood (2022) 140 (12): 1378–1389.

https://doi.org/10.1182/blood.2021014270

Published: 2022

Includes: Supplemental data

Journal Articles

Lentiviral-Mediated Gene Therapy for the Treatment of Adenosine Deaminase 2 Deficiency

Alessandra Mortellaro, Matteo Zoccolillo, Cristina Mesa Nuñez, Alessia Brix, Immacolata Brigida, Federica Barzaghi, Serena Scala, Raisa Jofra Hernández, Luca Basso-Ricci, Mariasilvia Colantuoni, Simone Cesaro, Francesca Conti, Andrea Pession, Fabio Benedetti, Marco Gattorno, Luigi Naldini, Maria Pia Cicalese, Anna Pistocchi, Alessandro Aiuti

Blood (2021) 138 (Supplement 1): 2937.

https://doi.org/10.1182/blood-2021-152127

Published: 2021

Journal Articles

Adding Romidepsin to CHOEP in First Line Treatment of Peripheral T-Cell Lymphomas Does Not Improve the Response Rate: Final Analysis of Phase II PTCL13 Study

Blood (2021) 138 (Supplement 1): 134.

https://doi.org/10.1182/blood-2021-153680

Published: 2021

Journal Articles

Phase II Multicenter, Not Comparative, Study of Multiple Doses of NEPA (netupitant + palonosetron) in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in Non-Hodgkin Lymphoma Patients Eligible for Autologous Hematopoietic Stem Cell Transplantation Receiving Multiple Days / High Dose Chemotherapy Regimens

Nicola Di Renzo, MD, Maurizio Musso, MD, Rosanna Scimè, MD, Giuseppe Milone, MD PhD, Tommasina Perrone, MD, Clara De Risi, MD, Domenico Pastore, MD PhD, Attilio Guarini, MD, Andrea Mengarelli, MD, Fabio Benedetti, MD, Patrizio Mazza, MD, Vera Capria, MD, Patrizia Chiusolo, Luca Cupelli, MD, Vincenzo Federico, MD, Valentina Bozzoli, PhD MD, Anna Rita Messa, Giorgina Specchia, MD

Blood (2019) 134 (Supplement_1): 1974.

https://doi.org/10.1182/blood-2019-125071

Published: 2019

Journal Articles

Comprehensive Minimal Residual Disease (MRD) Analysis of the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial for Younger Patients with Mantle Cell Lymphoma: A Kinetic Model Ensures a More Refined Risk Stratification

Blood (2018) 132 (Supplement 1): 920.

https://doi.org/10.1182/blood-2018-99-114442

Published: 2018

Journal Articles

Permissive HLA-DPB1 Mismatch and Survival after Unrelated Donor Allogeneic Stem Cell Transplantation for Hematological Malignancies: A Comparative Analysis of Different Immunogenetic Models on 422 Patients from GITMO and IBMDR

Francesca Lorentino, Nicoletta Sacchi, PhD BSc, Elena Oldani, MSc, Valeria Miotti, Alessandra Picardi, Anna Maria Gallina, Paolo Bernasconi, Riccardo Saccardi, MD, Lucia Farina, MD, Fabio Benedetti, Francesca Patriarca, MD, Michela Cerno, Benedetto Bruno, Alessandro Rambaldi, MD, Fabio Ciceri, MD, Katharina Fleischhauer, Luca Vago, MD PhD, Francesca Bonifazi

Blood (2018) 132 (Supplement 1): 482.

https://doi.org/10.1182/blood-2018-99-115216

Published: 2018

Journal Articles

High Resolution Donor/Recipient HLA Matching Level in Unrelated Hematopoietic Stem Cell Transplantation and Impact on the Transplant Outcome: The Italian Experience on Behalf of GITMO, IBMDR and Aibt

Blood (2018) 132 (Supplement 1): 4642.

https://doi.org/10.1182/blood-2018-99-114486

Published: 2018

Journal Articles

Prophylaxis with ATLG Significantly Improves Chronic Graft-Versus-Host Disease / Relapse-Free Survival and Quality of Life after a Myeloablative HLA Identical Sibling Transplant for Acute Leukemia Patients in Complete Remission. Long-Term Follow-up of the Randomized ATG Familystudy

Blood (2017) 130 (Supplement 1): 519.

https://doi.org/10.1182/blood.V130.Suppl_1.519.519

Published: 2017

Journal Articles

Erectile Dysfunction after Allogeneic Hematopoietic Stem Cell Transplant: Results from a Single Center Experience

Angelo Andreini, Nicola Zampieri, Claudio Costantini, Giovanni Malerba, Costanza Bruno, Gianluca Salvagno, Giuseppe Francia, Michele Gottardi, Michela Rimondini, Giuseppe Lippi, Isacco Ferrarini, Fabio Benedetti, Giovanni Pizzolo, Cristina Tecchio

Blood (2017) 130 (Supplement 1): 4530.

https://doi.org/10.1182/blood.V130.Suppl_1.4530.4530

Published: 2017

Journal Articles

Identification of DNA Copy Number Variations Associated with the Clinical Outcome in Young Mantle Cell Lymphoma Patients Treated with Cytarabine-Based High Dose Sequential Chemotherapy and Autologous Stem Cell Transplantation in the Prospective from the MCL0208 Phase III Trial from Fondazione Italiana Linfomi (FIL)

Andrea Rinaldi, PhD, Simone Ferrero, Ivo Kwee, PhD, Davide Rossi, MD PhD, Alessio Bruscaggin, Valeria Spina, Fary Diop, Filippo Ballerini, MD, Filippo Gherlinzoni, MD, Fabio Benedetti, Michael Mian, MD, Caterina Stelitano, MD, Elisa Doni, MD, Alessandra Flavia Salvi, Sergio Cortelazzo, Marco Ladetto, MD, Gianluca Gaidano, MD PhD, Francesco Bertoni, MD

Blood (2016) 128 (22): 4099.

https://doi.org/10.1182/blood.V128.22.4099.4099

Published: 2016

Journal Articles

Role of Allogeneic Stem Cell Transplantation (AlloSCT) in Patients Affected By Peripheral T-Cell Lymphomas (PTCL): No Difference in Outcome Between Patients Allografted at Diagnosis and in First Chemosensitive Relapse

Anna Dodero, MD, Francesco Spina, MD, Franco Narni, Francesca Patriarca, MD, Fabio Benedetti, MD, Donatella Baronciani, MD, Alessandro Rambaldi, Attilio Olivieri, MD, Serena Dalto, MD, Benedetto Bruno, MD, Umberto Vitolo, MD, Paolo Corradini, MD

Blood (2014) 124 (21): 2574.

https://doi.org/10.1182/blood.V124.21.2574.2574

Published: 2014

Journal Articles

Prevention of Chronic GvHD after HLA-Identical Sibling Peripheral Hematopietic Stem Cell Transplantation with or without Anti-Lymphocyte Globulin (ATG). Results from a Prospective, Multicenter Randomized Phase III Trial (ATGfamilystudy)

Blood (2014) 124 (21): 37.

https://doi.org/10.1182/blood.V124.21.37.37

Published: 2014

Journal Articles

Prolonged Survival Of Poor Risk Follicular Lymphoma Patients Following Primary Treatment With Rituximab-Supplemented CHOP Or HDS With Autograft: Long-Term Results Of The Multicenter Randomized GITMO/FIL Trial

Blood (2013) 122 (21): 551.

https://doi.org/10.1182/blood.V122.21.551.551

Published: 2013

Journal Articles

Intensified Chemo-Immunotherapy Including up-Front Autologous or Allogeneic Stem Cell Transplantation (SCT) for Young Patients with Newly Diagnosed Peripheral T-Cell Lymphomas: Final Results of a Phase II Multicenter Prospective Clinical Trial

Blood (2012) 120 (21): 1984.

https://doi.org/10.1182/blood.V120.21.1984.1984

Published: 2012

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Integrated multi-omic profiling identifies molecular subtypes and predicts outcomes in newly diagnosed peripheral T-cell lymphomas

Increased incidence of secondary malignancies after autologous stem cell transplantation in follicular lymphoma patients: Long-term results of the FIL-FLAZ12 Phase III randomized trial

Longitudinal Monitoring of Circulating Tumor DNA to Predict Survival in Newly Diagnosed Peripheral T-Cell Lymphoma Patients

Impact of Concurrent and Previous Multidrug Resistant Bacteria Colonization in Adult Allogenic Hematopoietic Stem Cell Transplant Patients with Acute Leukemia: A Single Center Retrospective Study

Impact of Fourth Methotrexate Dose in ATG-Cyclosporine GvHD Prophylaxis in HLA-Matched Unrelated HSCT: A GITMO Study

The Addition of Romidepsin to CHOEP and High-Dose Chemotherapy Plus Stem Cell Transplantation Did Not Ameliorate the Outcome of Untreated Angioimmunoblastic T-Cell or Follicular T-Helper Lymphoma: Subgroup Analysis of Phase II FIL-PTCL13 Study

Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma

Lentiviral-Mediated Gene Therapy for the Treatment of Adenosine Deaminase 2 Deficiency

Adding Romidepsin to CHOEP in First Line Treatment of Peripheral T-Cell Lymphomas Does Not Improve the Response Rate: Final Analysis of Phase II PTCL13 Study

Comprehensive Minimal Residual Disease (MRD) Analysis of the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial for Younger Patients with Mantle Cell Lymphoma: A Kinetic Model Ensures a More Refined Risk Stratification

Permissive HLA-DPB1 Mismatch and Survival after Unrelated Donor Allogeneic Stem Cell Transplantation for Hematological Malignancies: A Comparative Analysis of Different Immunogenetic Models on 422 Patients from GITMO and IBMDR

High Resolution Donor/Recipient HLA Matching Level in Unrelated Hematopoietic Stem Cell Transplantation and Impact on the Transplant Outcome: The Italian Experience on Behalf of GITMO, IBMDR and Aibt

Prophylaxis with ATLG Significantly Improves Chronic Graft-Versus-Host Disease / Relapse-Free Survival and Quality of Life after a Myeloablative HLA Identical Sibling Transplant for Acute Leukemia Patients in Complete Remission. Long-Term Follow-up of the Randomized ATG Familystudy

Erectile Dysfunction after Allogeneic Hematopoietic Stem Cell Transplant: Results from a Single Center Experience

Role of Allogeneic Stem Cell Transplantation (AlloSCT) in Patients Affected By Peripheral T-Cell Lymphomas (PTCL): No Difference in Outcome Between Patients Allografted at Diagnosis and in First Chemosensitive Relapse

Prevention of Chronic GvHD after HLA-Identical Sibling Peripheral Hematopietic Stem Cell Transplantation with or without Anti-Lymphocyte Globulin (ATG). Results from a Prospective, Multicenter Randomized Phase III Trial (ATGfamilystudy)

Prolonged Survival Of Poor Risk Follicular Lymphoma Patients Following Primary Treatment With Rituximab-Supplemented CHOP Or HDS With Autograft: Long-Term Results Of The Multicenter Randomized GITMO/FIL Trial

Intensified Chemo-Immunotherapy Including up-Front Autologous or Allogeneic Stem Cell Transplantation (SCT) for Young Patients with Newly Diagnosed Peripheral T-Cell Lymphomas: Final Results of a Phase II Multicenter Prospective Clinical Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only